We Live Open Science
A Different R&D Path that Defines the Company’s Position
The ecosystem delivering biopharmaceutical innovation has shifted. Where global pharma companies had previously discovered, developed and delivered new products from their own labs, the driving source of innovation today is coming from smaller biotechnology and pharma companies, as well as academia.
Given this shift in innovation origination, Allergan has sought to follow a different R&D path than other companies. We embrace an Open Science model. It defines the Company’s position in this new ecosystem – as a magnet for game-changing ideas and innovation. A large percentage of our pipeline is sourced by partnering with biotech companies, academia and other pharmaceutical companies globally. Through this Open Science model, we drive strong R&D productivity by delivering innovative therapies that create long-term shared value for Allergan, for customers and for patients.
Open Science has helped to build leadership in several therapeutic areas and drive the Company's long-term growth. Today, Allergan is rich with programs in development across our seven therapeutic areas, with key candidates for global development in Medical Aesthetics and Dermatology, Eye Care, Central Nervous System disorders, Gastroenterology, Women’s Health, Urology and Anti-infectives.
Through our Open Science strategy, we have added product opportunities from the innovation ecosystem across our key therapeutic areas, including Rapastinel, TrueTear, XEN Gel Stent, Cenicriviroc, Relamorelin, Ubrogepant/Atogepant and Esmya.
All programs enter into our best-in-class product development and commercialization organization to build a sustainable development portfolio that addresses unmet needs and aligns with our key therapeutic areas.
Allergan is committed to this strategy, and to continuing to invest significant dollars in R&D annually.